[PI3K-AKT-mTOR pathway and cancer].

Abstract

PI3K/AKT/mTOR pathway is an intracellular signalling pathway composed of different kinases. Many protein mutations are described in that pathway, and are responsible of dysregulation of cell growth, proliferation, survival and angiogenesis. Rapamycin is an antibiotic inhibiting mTOR. Different analogs of rapamycin are developed or being developed in antitumoral therapy, in which temsirolimus, everolimus and deforolimus, demonstrated antitumoral activity in renal cancer and mantle cell lymphoma, and many clinical trials are in progress in other tumors. In the future, predictive factors of response need to be identified; patient selection and associations with chemotherapy or with other targeted therapies should be explored.

• Authors: Laetitia Coutte, Chantal Dreyer, Marie-Paule Sablin, Sandrine Faivre, Eric Raymond
• Journal: Bulletin du cancer (Bull Cancer) Vol. 99 Issue 2 Pg. 173-80 (Feb 01 2012) ISSN: 1769-6917 [Electronic] France
• Vernacular Title: Rôle de la voie PI3K-AKT-mTOR dans le cancer et les thérapeutiques antitumorales.
• PMID: 21742593 (Publication Type: Journal Article, Review)

Chemical References

• Phosphoinositide-3 Kinase Inhibitors
• ridaforolimus
• temsirolimus
• Everolimus
• MTOR protein, human
• Oncogene Protein v-akt
• TOR Serine-Threonine Kinases
• Sirolimus

Topics

• Carcinoma, Renal Cell (drug therapy)
• Everolimus
• Humans
• Kidney Neoplasms (blood supply, drug therapy, metabolism)
• Lymphoma, Mantle-Cell (drug therapy)
• Neovascularization, Pathologic (drug therapy, etiology)
• Oncogene Protein v-akt (antagonists & inhibitors, physiology)
• Phosphatidylinositol 3-Kinases (physiology)
• Phosphoinositide-3 Kinase Inhibitors
• Signal Transduction (drug effects, physiology)
• Sirolimus (analogs & derivatives, pharmacology)
• TOR Serine-Threonine Kinases (antagonists & inhibitors, physiology)